History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature
Authors:
- Chiara LazzariCLChiara Lazzari
- Aurora MirabileAMAurora Mirabile
- Alessandra BulottaABAlessandra Bulotta
- Maria Grazia ViganóMVMaria Grazia Viganó
- Francesca Rita OgliariFOFrancesca Rita Ogliari
- Stefania IppatiSIStefania Ippati
- Italo DellOcaIDItalo DellOca
- Mariacarmela SantarpiaMSMariacarmela Santarpia
- Vincenza LorussoVLVincenza Lorusso
- Martin ReckMRMartin Reck
- Vanesa GregorcVGVanesa Gregorc
Open Access
Abstract
Several trials have tried for decades to improve the outcome of extensive disease small cell lung cancer (ED-SCLC) through attempts to modify the standard treatments. Nevertheless, platinum/etoposide combination and topotecan have remained respectively the first and the second line standard treatments for the last 40 years. With the advent of immunotherapy, this scenario has finally changed. Our review aims to provide an overview of the primary studies on the actual therapeutic strategies available for ED-SCLC patients, and to highlight emerging evidence supporting the use of immunotherapy in SCLC patients.Keywords
This publication has 61 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnnals of Oncology, 2012
- A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of ImmunotherapyThe Journal of Immunology, 2012
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responsesBritish Journal of Cancer, 2009
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124Journal of Clinical Oncology, 2009
- Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III TrialJournal of Clinical Oncology, 2008
- Regulatory T cells in paraneoplastic neurological syndromesJournal of Neuroimmunology, 2008
- A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysisLung Cancer, 2000
- PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancersOncogene, 1998